Despite significant scientific advancements, the promise of gene therapy has yet to be realized, due in part to the limitations of conventional gene delivery systems. Symvivo’s bacTRL™ Gene Therapy Platform is designed and optimized to address these barriers, which include the inability to accommodate large or multi- genes, the lack of specificity to targeted tissue and poor control over immune response.  The bacTRL™ platform enables oral and intravenous vaccines to selectively colonize hypoxic tissue, while simultaneously being cleared from healthy tissues.

Throughout the life of the colony, the bacteria produce and deliver genetic material to the surrounding tissues, providing consistent and progressive levels of gene delivery and expression.

bacTRL Platform Diagram